63010-09-3

Usage

Uses

Used in Organic Synthesis:
[1-(4-chlorophenyl)cyclobutyl]methanamine is used as a synthetic intermediate for the preparation of various organic compounds. Its cyclobutyl carbinamine moiety and 4-chlorophenyl substituent provide a versatile platform for chemical reactions, enabling the synthesis of a range of molecules with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [1-(4-chlorophenyl)cyclobutyl]methanamine may be utilized as a starting material or a building block in the development of new drugs. Its unique structure could offer novel pharmacological properties, making it a valuable candidate for drug discovery and optimization processes. Researchers may explore its potential as a precursor for the synthesis of bioactive molecules targeting specific therapeutic areas, such as central nervous system disorders, cardiovascular diseases, or oncology.

InChI:InChI=1/C11H14ClN/c12-10-4-2-9(3-5-10)11(8-13)6-1-7-11/h2-5H,1,6-8,13H2

Upstream product

• 28049-61-8 1-(4-chlorophenyl)cyclobutanecarbonitrile 
• 140-53-4 p-chlorobenzyl cyanide 

Downstream Products

• 147406-41-5 1-(4-chlorophenyl)-N-methylcyclobutanemethanamine 

Relevant academic research and scientific papers

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

A study and identification of potential by-products of sibutramine

In the synthesis and process development of sibutramine (9), the isolation and characterization of two potential by-products namely heptane dinitriles (4a-b) and bis-cyclobutyl alkylamine (10) have been studied. The key steps in the synthesis of sibutramine which have contributed to the formation of above by-products are cycloalkylation of 4-chlorophenyl acetonitrile (1) and tandem Grignard reduction on 1-(4-chlorophenyl)cyclobutyl carbonitrile (3).

Multidrug resistance modifying dithianes

Compounds of the formula STR1 wherein R is a residue of the formula STR2 and R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as described, with the exception of rac-N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-β,N-dimethyl-m-dithiane-2-propanamine, as well as their acid addition salts, in particular for use in eliminating cytostatic resistance in tumor treatment and chloroquine resistance in malaria.